Alec Titan
Congenital muscular dystrophy (CMD) is a group of neuromuscular disorders with onset at birth or infancy, characterised by hypotonia, muscle wasting, weakness, or delayed motor milestones. CMD is caused by genetic mutations affecting proteins necessary for muscles and sometimes the eyes and brain. The symptoms of muscular dystrophy vary depending on the type, but the main symptom is muscle weakness and other muscle-related issues. CMD is diagnosed based on clinical findings, immunochemical staining on muscle biopsy, and molecular genetic testing.
| Characteristics | Values |
|---|---|
| Definition | Congenital muscle disease refers to a group of more than 30 genetic conditions that affect muscle function and are present at birth. |
| Cause | Congenital muscle disease is caused by [genetic mutations] affecting [proteins necessary for muscles] and, sometimes, the eyes and brain. |
| Symptoms | Symptoms include [muscle weakness], [hypotonia], [muscle wasting], [delayed motor milestones], [increased reflexes], [involuntary muscle spasms] and [stiff movements of the legs]. |
| Diagnosis | Congenital muscle disease is diagnosed based on [clinical findings], [immunochemical staining on muscle biopsy] and [molecular genetic testing]. |
| Treatment | Treatment includes [nutritional support] and [psychological support] for patients and families. |
| Prognosis | The prognosis depends on the [type of congenital muscle disease]. [Respiratory insufficiency] and [brain pathology] are the [main causes of mortality]. |
Explore related products
What You'll Learn
- Congenital muscular dystrophy is a group of neuromuscular disorders with onset at birth or infancy
- The disease is caused by genetic mutations affecting proteins necessary for muscles and sometimes the eyes and brain
- CMD has many forms, including Duchenne and Becker dystrophy, Fukuyama Type, and Walker-Warburg Syndrome
- Diagnosis is based on clinical findings, immunochemical staining on muscle biopsy, and molecular genetic testing
- Treatment and management include nutritional support, psychological help, and developing therapies for the disease
Congenital muscular dystrophy is a group of neuromuscular disorders with onset at birth or infancy
Congenital muscular dystrophy (CMD) is a group of muscular dystrophies that are either present at birth or become evident in infancy, typically before the age of 2. CMD is caused by genetic mutations affecting some of the proteins necessary for muscles and, in some cases, the eyes and brain. The symptoms of CMD include overall muscle weakness, with possible joint stiffness or looseness, and spinal curvature (scoliosis). Depending on the type, CMD may also cause breathing issues, intellectual disabilities, learning disabilities, vision and speech problems, seizures, and structural changes in the brain.
The degree and progression of muscle weakness and degeneration vary with the type of CMD. Weakness may first be noted when children do not meet developmental milestones related to motor function and muscle control. Most people with CMD are unable to sit or stand without support, and some may never learn to walk. CMD can also cause muscle atrophy, difficulty walking, climbing stairs, or running, and an irregular walking gait.
There are many genetic forms of CMD, including merosin-negative disorders, where the protein merosin (found in the connective tissue surrounding muscle fibers) is missing, and merosin-positive disorders, where merosin is present but other necessary proteins are missing. Other congenital dystrophies include Walker-Warburg syndrome, muscle-eye-brain disease, and Fukuyama disease, which are together called dystroglycanopathies due to mutations in a common protein called dystroglycan.
The prognosis for individuals with CMD depends on the specific type of dystrophy, with respiratory insufficiency and brain pathology being the main causes of mortality. While there is currently no cure for CMD, supportive treatments and nutritional management play a significant role in the long-term management of the condition. Orthopedic complications, such as joint contractures and spinal deformities, are a primary concern and require preventive or proactive treatment.
Understanding Muscle Origin and Functionality
You may want to see also
Explore related products
The disease is caused by genetic mutations affecting proteins necessary for muscles and sometimes the eyes and brain
Congenital muscular dystrophy (CMD) is a group of muscular dystrophies that are present at or near birth. It is caused by genetic mutations affecting proteins necessary for muscles and, in some cases, the eyes and brain. CMD results in overall muscle weakness, with possible joint stiffness or looseness, and can cause spinal curvature, respiratory insufficiency, intellectual and learning disabilities, eye defects, or seizures. The disease is degenerative and primarily affects voluntary muscles.
CMD is caused by genetic mutations that interfere with the creation of proteins necessary for muscle function. These mutations can be inherited or occur spontaneously, and they affect the structure and function of proteins, leading to muscle weakness. The most common forms of congenital muscular dystrophies result from alterations in plasma membrane surface proteins or those forming part of the membrane-extracellular matrix interface. For example, Duchenne and Becker dystrophy result from a mutation in the dystrophin gene. Duchenne dystrophy occurs when the protein is abnormally truncated, while Becker dystrophy arises from partially functional dystrophin.
Congenital myopathies are a specific type of CMD that causes problems with the tone and contraction of skeletal muscles, which control voluntary movements. These myopathies are usually non-progressive, meaning they do not worsen over time. They are often caused by mutations that affect filament proteins, which are necessary for muscle contraction and tone. When these filament proteins do not function properly, muscles cannot contract, leading to a loss of tone and strength. Central core disease, for instance, damages muscles by causing an excess release of calcium from internal storage compartments.
While congenital myopathies do not typically cause muscle death, they prevent them from functioning correctly. Researchers have identified many of the genes that cause various forms of CMD, leading to advancements in diagnosis and treatment strategies. There is currently no cure for muscular dystrophy, but treatments aim to manage symptoms and improve patients' quality of life. Nutritional support also plays a significant role in the long-term management of CMD patients, as they are usually underweight, and macro/micronutrient deficiencies can exacerbate underlying muscle weakness.
Muscle Failure: Is It Essential for Growth?
You may want to see also
Explore related products
CMD has many forms, including Duchenne and Becker dystrophy, Fukuyama Type, and Walker-Warburg Syndrome
Congenital Muscle Disease (CMD) is caused by genetic mutations affecting proteins necessary for muscles and, in some cases, the eyes and brain. CMD has its onset at or near birth, and its progression varies depending on the type. While some types of CMD progress slowly, others can shorten life spans.
CMD has many forms, including Duchenne and Becker muscular dystrophy, Fukuyama Type, and Walker-Warburg Syndrome. Duchenne muscular dystrophy (DMD) is a genetic disorder characterised by progressive muscle degeneration and weakness. It is caused by alterations in a protein called dystrophin, which helps keep muscle cells intact. DMD primarily affects boys, with onset symptoms usually appearing between the ages of 2 and 3. Becker muscular dystrophy (BMD) is similar to DMD but has a later onset, usually in the teens or early adulthood, and milder symptoms. BMD affects the muscles of the hips, pelvic area, thighs, and shoulders, as well as the heart.
Fukuyama congenital muscular dystrophy is an inherited condition predominantly affecting the muscles, brain, and eyes. It causes muscle weakness and wasting, with symptoms typically beginning in early infancy, including a weak cry, difficulty feeding, and weak muscle tone. Fukuyama congenital muscular dystrophy also impairs brain development, often resulting in a brain abnormality called cobblestone lissencephaly, which leads to delays in motor skill and speech development and intellectual disabilities.
Walker-Warburg syndrome is an inherited disorder that affects the development of the muscles, brain, and eyes. It is the most severe form of congenital muscular dystrophy, causing muscle weakness and wasting beginning very early in life. Affected babies have weak muscle tone and are sometimes described as "floppy." Walker-Warburg syndrome also affects the brain, resulting in cobblestone lissencephaly, a brain abnormality characterised by a bumpy and irregular brain surface. Due to the severity of the condition, most individuals with Walker-Warburg syndrome do not survive past childhood.
Activating Muscles: The Chemical Behind Movement
You may want to see also
Explore related products
Diagnosis is based on clinical findings, immunochemical staining on muscle biopsy, and molecular genetic testing
Congenital muscular dystrophy (CMD) is a group of muscular dystrophies that manifest at or near birth. It is characterised by muscle weakness and possible joint stiffness, looseness, spinal curvature, respiratory insufficiency, intellectual disabilities, learning disabilities, eye defects, or seizures. CMD is caused by genetic mutations affecting proteins necessary for muscles and sometimes the eyes and brain.
Diagnosis of CMD is challenging due to its clinical, immunohistochemical, and genetic heterogeneity. It involves a comprehensive approach, including clinical findings, immunochemical staining on muscle biopsy, and molecular genetic testing.
Clinical Findings
The diagnosis of CMD often begins with a clinical examination, where a physician evaluates the patient's medical history, family history, and physical symptoms. Increased creatine kinase (CK) levels, the presence of intellectual deficiency, and the distribution of various signs and symptoms can help distinguish different forms of CMD.
Immunochemical Staining on Muscle Biopsy
A muscle biopsy is a critical tool in diagnosing CMD. It involves extracting a small sample of muscle tissue for analysis. Immunochemical staining techniques are then applied to this sample to identify the presence of dystrophic features characteristic of CMD. This process helps differentiate CMD from other muscular disorders.
Molecular Genetic Testing
Molecular genetic testing plays a pivotal role in confirming a CMD diagnosis. It involves analysing the patient's DNA to identify mutations in specific genes associated with CMD. This testing is particularly useful in prenatal diagnosis, where molecular analysis of amniocytes, coupled with immunohistochemical staining of chorionic villus samples, can detect the presence of CMD before birth.
While diagnosis is a complex and challenging process, advancements in molecular diagnostic techniques have improved the accuracy of CMD identification. Accurate diagnosis is essential for appropriate management and support, as there is currently no curative therapy for CMD.
Muscle Shrinkage at Night: Fact or Fiction?
You may want to see also
Explore related products
Treatment and management include nutritional support, psychological help, and developing therapies for the disease
Congenital muscular dystrophy (CMD) is a group of muscular dystrophies that are apparent at or near birth. It is a genetic, degenerative disease that primarily affects voluntary muscles. The disease causes overall muscle weakness, with possible joint stiffness or looseness, and may also involve spinal curvature, respiratory insufficiency, intellectual disabilities, learning disabilities, eye defects, or seizures. CMD is caused by genetic mutations affecting the proteins necessary for muscles and, in some cases, the eyes and brain.
CMD treatment and management include nutritional support, psychological help, and developing therapies for the disease. Nutritional support is essential for long-term management as patients are typically underweight, and macro/micronutrient deficiencies can exacerbate underlying muscle weakness. Psychological support is also crucial, as many patients with normal intellectual ability require assistance in dealing with the stress of living with a chronic disease.
Developing therapies for CMD focus on treating the symptoms and include orthopedic treatment, physical therapy, occupational therapy, and speech therapy. Further experimental treatments, such as gene therapies, are still being developed. For instance, the drug albuterol has been shown to lessen muscle weakness in children with central core disease and multicore disease, although it is not a cure.
Advances in diagnosis and treatment strategies for CMD have been made possible by researchers identifying many of the genes that cause various forms of the disease. This improved understanding of the disease has led to the development of treatments and therapies to improve patients' quality of life and outcomes.
Treating Muscle Dysmorphia: Therapy and Beyond
You may want to see also
